Citrulline 100mg tablets
Requires a prescription from a doctor or prescriber
Citrulline is an amino acid.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · Randomised trials: 8 · 1939–2026
Showing the 50 most relevant studies, sorted by most relevant.
Konstantinos C. Fragkos, Alastair Forbes
United European Gastroenterology Journal, 2017
Eric T Trexler, A. Persky, E. Ryan, et al.
Sports Medicine, 2019
Timothy D. Allerton, David N. Proctor, Jacqueline M. Stephens, et al.
Nutrients, 2018
- Anti-Inflammatory Agents, Non-Steroidal
- Antihypertensive Agents
- Antioxidants
H. Rhim, Sung Jong Kim, Jewel Park, et al.
Journal of Sport and Health Science, 2020
Takashi Suzuki, M. Morita, Yoshinori Kobayashi, et al.
Journal of the International Society of Sports Nutrition, 2016
Luo P, Li Z, Liu K, et al.
2025
ObjectivesTo determine and explore the effects of L-citrulline supplementation and watermelon intake on arterial stiffness (AS) and endothelial function in middle-aged and elderly individuals.ParticipantsMiddle-aged and elderly adults.DesignsA systematic review and meta-analysis of randomized controlled trials (RCTs).MethodsA comprehensive search was conducted across four major electronic databases (PubMed, Cochrane, EMBASE, and Web of Science), covering the period from database inception to May 1, 2025. The quality of included studies was assessed using the Cochrane Risk of Bias Assessment tool 2.0. Data analysis was performed with RevMan 5.4.1 software; pulse wave velocity (PWV) data were analyzed using a random-effects model to pool effect sizes, while flow-mediated dilation (FMD) data were analyzed using a fixed-effects model to pool effect sizes. Heterogeneity was evaluated using the chi-square-based Cochran's Q test (p I 2 statistic.ResultsThis systematic review and meta-analysis included 8 RCTs with a total of 176 participants. The results showed that L-citrulline supplementation significantly improved FMD [1.81 (95% CI: 0.76 to 2.85), p = 0.0007]. Although L-citrulline supplementation did not significantly improve PWV [-0.14 (95% CI: -0.45 to 0.17), p = 0.37], a trend toward improvement was observed. Subgroup analyses indicated that L-citrulline supplementation had the most significant effect on ankle-brachial pulse wave velocity (BA-PWV) [-1.11 (95% CI: -1.37 to -0.85), p ConclusionSupplementation with L-citrulline has a positive impact on vascular function in middle-aged and elderly individuals, significantly improving FMD. However, although there was no improvement in PWV, subgroup analysis results still show that L-citrulline supplementation significantly reduced BA-PWV. This suggests that this intervention may have potential application value in preventing and improving the risk of cardiovascular diseases (CVDs) in this population. However, watermelon intake did not significantly improve FMD and PWV in middle-aged and older adults, and there is insufficient relevant literature. Future large-scale studies are needed to confirm the effects of watermelon on vascular function.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/CRD420251052954.
Abstract licence: CC BY
Luo P, Chen J, Liu K, et al.
2026
The primary objective of this systematic review and meta-analysis is to investigate whether L-citrulline supplementation can counteract the adverse effects of cold environments on individual blood pressure (BP), providing scientific evidence for the clinical development and application of L-citrulline as a cardiovascular protective nutritional supplement. A comprehensive search was conducted across four electronic databases: PubMed, Cochrane Library, Embase, and Web of Science. The search period was limited from database inception to May 28, 2025. The Cochrane Risk of Bias tool and JADAD scoring scale were used to assess risk of bias and literature quality of the included randomized controlled trials (RCTs). Statistical analysis of BP data was performed using RevMan 5.4.1 software, employing both random-effects and fixed-effects models for data analysis, and forest plots were generated. The overall intervention effect was evaluated using the weighted mean difference (WMD) and its 95% confidence interval (CI). A total of 6 RCTs investigating the effects of L-citrulline intake on BP in cold environments were included, involving 162 participants (intervention group: 87; control group: 75). Results indicate that L-citrulline intake significantly reduced cold-induced SBP (-9.28 mmHg [95% CI: -10.66 to -7.90], p p = 0.01). Subgroup analysis revealed significant reductions in brachial SBP (-8.74 mmHg [95% CI: -10.61 to -6.88], p p p p = 0.13). Meta-analysis results indicate that L-citrulline supplementation can significantly improve cold exposure-induced BP elevation, providing scientific evidence for the clinical development and application of cardiovascular protective nutritional supplements.
Abstract licence: CC BY
Bahari H, Ramezani E, Malekahmadi M
2026
- Muscle, Skeletal
- Citrulline
- Postmenopause
S. Azizi, R. Mahdavi, Elnaz Vaghef-Mehrabany, et al.
Clinical and Experimental Pharmacology and Physiology, 2020
K. A. Wijnands, T. Castermans, Merel P.J. Hommen, et al.
Nutrients, 2015
- Immunity
- Arginine
- Citrulline
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
Not available
Mechanism
L-citrulline is converted to L-arginine by argininosuccinate synthase.
Food interactions
None known
Human targets
12 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 137 interactions
Proteins and enzymes this drug interacts with in the body
PMID:1378832
NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets
PMID:21493890 PMID:37296100
In endothelial cells, induces expression of vascular endothelial growth factor (VEGF) via phosphorylation of the transcription factor SP1 by PKA in a process that is independent of NO and NO synthase (By similarity). Similarly, enhances pancreatic insulin secretion through SP1-mediated transcriptional up-regulation of secretagogin/SCGN, an insulin vesicle docking protein (By similarity).
Upon viral infection, relocates to mitochondria where it promotes mitochondrial fission through activation of DNM1L leading to the inhibition of innate response activation mediated by MAVS PMID:33850055
PMID:2556444 PMID:6372096 PMID:8112735
The urea cycle ensures the detoxification of ammonia by converting it to urea for excretion PMID:2556444
Proteins that transport this drug across cell membranes
PMID:11669456 PMID:11907186 PMID:14675047 PMID:22108572 PMID:23832370 PMID:28534121 PMID:9950961
Mediates the uptake of OA across the basolateral side of proximal tubule epithelial cells, thereby contributing to the renal elimination of endogenous OA from the systemic circulation into the urine .
PMID:9887087
Functions as a biopterin transporters involved in the uptake and the secretion of coenzymes tetrahydrobiopterin (BH4), dihydrobiopterin (BH2) and sepiapterin to urine, thereby determining baseline levels of blood biopterins .
PMID:28534121
Transports prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) and may contribute to their renal excretion .
PMID:11907186
Also mediates the uptake of cyclic nucleotides such as cAMP and cGMP .
PMID:26377792
Involved in the transport of neuroactive tryptophan metabolites kynurenate (KYNA) and xanthurenate (XA) and may contribute to their secretion from the brain .
PMID:22108572 PMID:23832370
May transport glutamate .
PMID:26377792
Also involved in the disposition of uremic toxins and potentially toxic xenobiotics by the renal organic anion secretory pathway, helping reduce their undesired toxicological effects on the body .
PMID:11669456 PMID:14675047
Uremic toxins include the indoxyl sulfate (IS), hippurate/N-benzoylglycine (HA), indole acetate (IA), 3-carboxy-4- methyl-5-propyl-2-furanpropionate (CMPF) and urate .
PMID:14675047 PMID:26377792
Xenobiotics include the mycotoxin ochratoxin (OTA) .
PMID:11669456
May also contribute to the transport of organic compounds in testes across the blood-testis-barrier PMID:35307651
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Citrulline
Additional database identifiers
ChemSpider
9367
BindingDB
92903
PDB
CIR
Guide to Pharmacology
722
ZINC
ZINC000001532614
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7876
GenAtlas
NOS3
GeneCards
NOS3
GenBank Gene Database
M93718
GenBank Protein Database
189212
Guide to Pharmacology
1249
UniProt Accession
NOS3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:758
GenAtlas
ASS1
GeneCards
ASS1
GenBank Gene Database
X01630
GenBank Protein Database
28872
UniProt Accession
ASSY_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2716
GenAtlas
DDAH2
GeneCards
DDAH2
GenBank Gene Database
AF070667
GenBank Protein Database
4454710
UniProt Accession
DDAH2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2715
GenAtlas
DDAH1
GeneCards
DDAH1
GenBank Gene Database
AB001915
GenBank Protein Database
4160666
Guide to Pharmacology
1247
UniProt Accession
DDAH1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8512
GenAtlas
OTC
GeneCards
OTC
GenBank Gene Database
K02100
GenBank Protein Database
189407
UniProt Accession
OTC_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7872
GenAtlas
NOS1
GeneCards
NOS1
GenBank Gene Database
U17327
GenBank Protein Database
642526
Guide to Pharmacology
1251
UniProt Accession
NOS1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7873
GenAtlas
NOS2A
GeneCards
NOS2
GenBank Gene Database
L09210
GenBank Protein Database
292242
Guide to Pharmacology
1250
UniProt Accession
NOS2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18368
GenAtlas
PADI4
GeneCards
PADI4
GenBank Gene Database
AB017919
GenBank Protein Database
5913971
Guide to Pharmacology
2877
UniProt Accession
PADI4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:20449
GenAtlas
PADI6
GeneCards
PADI6
GenBank Gene Database
AY422079
GenBank Protein Database
40068449
UniProt Accession
PADI6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18367
GenAtlas
PADI1
GeneCards
PADI1
GenBank Gene Database
AB033768
GenBank Protein Database
6116899
Guide to Pharmacology
2894
UniProt Accession
PADI1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18337
GenAtlas
PADI3
GeneCards
PADI3
GenBank Gene Database
AB026831
GenBank Protein Database
6172379
UniProt Accession
PADI3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18341
GenAtlas
PADI2
GeneCards
PADI2
GenBank Gene Database
AB030176
GenBank Protein Database
5572747
UniProt Accession
PADI2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10970
GenAtlas
hROAT1
GeneCards
SLC22A6
GenBank Gene Database
AF057039
GenBank Protein Database
3831566
Guide to Pharmacology
1025
UniProt Accession
S22A6_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q106345633), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.